Episode 13: Vulval skin conditions - Part 2: Management

02/06/23 • 22 min

In this episode our host Dr Justin Bui speaks to Dr Fiona Lewis about vulval skin conditions.
In this episode we discuss...

· Management of lichen sclerosus, including what to do when topical steroids are not effective

· Management of vulval eczema and psoriasis

· When to refer to a tertiary service
Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.

In this episode our host Dr Justin Bui speaks to Dr Fiona Lewis about vulval skin conditions.
In this episode we discuss...

· Management of lichen sclerosus, including what to do when topical steroids are not effective

· Management of vulval eczema and psoriasis

· When to refer to a tertiary service
Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.

Previous Episode

Episode 12: Vulval skin conditions - Part 1: History and Examination

In this episode our host Dr Justin Bui speaks to Dr Fiona Lewis about vulval skin conditions.
In this episode we discuss...

· Common presentations of vulval skin conditions

· Diagnostic clues in the history

· Clinical examination

· When to consider further investigations including a biopsy
Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.

Next Episode

Episode 15: Part 2: Immunobullous disorders - Pemphigus vulgaris

In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about pemphigus vulgaris:

• The clinical features of pemphigus vulgaris and other variants of pemphigus.
• The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin .

Resources and further reading:
• British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris, 2017 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930)
• European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752)
• Rituximab and Covid-19 Risk – a single-centre cohort study (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext)
• Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (https://pubmed.ncbi.nlm.nih.gov/35686647/)
• Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (https://pubmed.ncbi.nlm.nih.gov/34608631/)

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.

Recorded date: 26 January 2024